Avacta Group plc (GB:AVCT) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Avacta Group plc has announced successful completion of their first cohort and initiated dosing in the second cohort of their AVA6000 Phase 1 trial, which includes a FAPI-PET sub-study to enhance tumor targeting. The trial evaluates AVA6000, leveraging their pre|CISION™ technology to deliver doxorubicin chemotherapy with improved safety. The company remains on track with their goals for the second half of 2024, anticipating the commencement of a Phase 1b efficacy study and further data presentations.
For further insights into GB:AVCT stock, check out TipRanks’ Stock Analysis page.
